NEWS

Renowned Gastroenterologist, Dr. Adam S. Cheifetz, Joins AegirBio’s Scientific Advisory Board

 AegirBio AB announces the appointment of Dr. Adam S. Cheifetz to its Scientific Advisory Board.

Dr. Cheifetz, Director of the Center for Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School, brings unparalleled expertise in the field of gastroenterology, particularly in the treatment of Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases.

"We are honoured to welcome Dr. Cheifetz to our Scientific Advisory Board. His extensive knowledge, ground-breaking research, and leadership in the field of gastroenterology will undoubtedly enhance our scientific vision and drive innovation in our pursuits," said Marco Witteveen (CEO, AegirBio AB).

A magna cum laude graduate from Brown University and a distinguished alumnus of Cornell University Medical College, Dr. Cheifetz has an impressive track record in both clinical practice and research. His pioneering work in therapeutic drug monitoring and optimizing the use of biologics has significantly contributed to advancements in patient care.

As a member of our Scientific Advisory Board, Dr. Cheifetz will play a pivotal role in guiding our mission, empowering people to monitor health, improve treatment and quality of life. His wealth of experience and commitment to excellence align seamlessly with our values, and we look forward to a fruitful collaboration.

Dr. Cheifetz expressed enthusiasm about becoming a scientific advisor for AegirBio AB: "I am excited to be part of the Scientific Advisory Board and contribute to the work AegirBio is doing in Therapeutic Drug Monitoring using saliva as the sample type. I look forward to working with the team at AegirBio to advance innovation and make a meaningful scientificimpact.”

AegirBio is confident that Dr. Cheifetz's addition to the Scientific Advisory Board will further strengthen the company's scientific view. We eagerly anticipate leveraging his insights to drive advancements that will benefit the broader community.

About Aegirbio

AegirBio is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, AegirBio was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Aegirbio's website www.aegirbio.com

The company's Certified Adviser is Eminova Fondkomission AB | 08-684 211 00 | info@eminova.se

Related link:
Cision